Barclays Upgrades Revance Therapeutics Price Target to $40.00 for 2023
March 11, 2023
Trending News 🌥️
Barclays recently upgraded Revance Therapeutics ($NASDAQ:RVNC), setting the price target for 2023 at $40.00. Revance Therapeutics is a specialty biopharmaceutical company that specializes in the development of innovative injectable and topical products for medical aesthetic and therapeutic indications. Barclays believes that these treatments have the potential to revolutionize the medical aesthetic and therapeutic space, and this belief is reflected in the upgraded price target. In addition to the potential of its innovative treatments, Barclays views Revance as a valuable acquisition target for larger healthcare companies.
The company’s strong pipeline of treatments, as well as its efficient, cost-effective development process, make it an attractive prospect for potential acquirers. This new target reflects the company’s strong potential for growth and its value as an acquisition target. With Revance’s innovative treatments in the pipeline, the future of this specialty biopharmaceutical company is looking very bright indeed.
Market Price
This is a sign that investors are wary of the company’s long-term prospects despite the analyst’s bullish outlook. Nonetheless, the upgrade from Barclays has given many investors reason to believe that Revance Therapeutics could be a good investment for the long-term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Revance Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 132.56 | -356.42 | -237.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Revance Therapeutics. More…
| Operations | Investing | Financing |
| -193.55 | -138.8 | 331.69 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Revance Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 581.9 | 569.3 | 0.15 |
Key Ratios Snapshot
Some of the financial key ratios for Revance Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 584.7% | – | -255.9% |
| FCF Margin | ROE | ROA |
| -163.4% | -267.9% | -36.4% |
Analysis
GoodWhale can help you to analyze REVANCE THERAPEUTICS‘s fundamentals in order to make a better-informed investment decision. GoodWhale’s Risk Rating of REVANCE THERAPEUTICS shows that it is a medium risk investment when it comes to financial and business aspects. We have identified 2 risk warnings in the balance sheet and cashflow statement of REVANCE THERAPEUTICS, which can be seen by registering on GoodWhale.com. In this way, we provide insights into the potential risks associated with investing in REVANCE THERAPEUTICS so that you can make an informed decision. More…
Peers
In the realm of aesthetic treatments, there is fierce competition among companies to develop the most innovative and effective products. Among these companies is Revance Therapeutics Inc, which is up against tough competition from Viva Biotech Holdings, Pharmaron Beijing Co Ltd, and CStone Pharmaceuticals. All of these companies are vying to create the best products and treatments that will appeal to consumers.
– Viva Biotech Holdings ($SEHK:01873)
Viva Biotech Holdings is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of various diseases. The company’s lead product candidate is VB-111, a first-in-class, targeted anti-cancer agent that is in Phase III clinical development for the treatment of glioblastoma, the most common and aggressive form of brain cancer. Viva Biotech has a market cap of 2.28B as of 2022 and a Return on Equity of 5.39%.
– Pharmaron Beijing Co Ltd ($SZSE:300759)
Pharmaron Beijing Co., Ltd. is a global, research-based drug discovery and development company that partners with life science organizations to transform the way therapeutics are discovered and developed. The company’s services include target identification and validation, lead optimization, preclinical and clinical research, and commercialization. Pharmaron Beijing Co., Ltd. is headquartered in Beijing, China.
– CStone Pharmaceuticals ($OTCPK:CSPHF)
CStone Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative immuno-oncology therapeutics. The company’s market cap is 508.8M as of 2022 and its ROE is -87.18%. CStone Pharmaceuticals is focused on developing and commercializing immuno-oncology therapies that target the tumor microenvironment and modulate the immune system to fight cancer. The company’s lead product candidate, CS1001, is a PD-L1/TGF-β inhibitor that is being evaluated in a global Phase III clinical trial in first-line non-small cell lung cancer.
Summary
Revance Therapeutics is an American biotechnology company focused on developing treatments for wrinkles and muscle movement disorders. Recently, Barclays has upgraded their price target for Revance to $40.00 for 2023, suggesting that the company has potential for growth in the near future. Revance has reported promising results from its trials thus far, leading analysts to have faith in their potential for success. With Barclays’ upgrade, Revance appears to be a strong investment opportunity for those looking for long-term returns.
